© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) stock remained unchanged at $10.00 a share on NASDAQ. The stock opened at $10.32, fluctuating between $9.79 to $10.45 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 16, 2026 | 10.31 | 10.49 | 9.79 | 10.00 | 102.68K |
| Jun 15, 2026 | 9.89 | 10.14 | 9.46 | 10.00 | 159.83K |
| Jun 12, 2026 | 10.08 | 10.28 | 9.47 | 9.61 | 80.72K |
| Jun 11, 2026 | 10.00 | 10.36 | 9.70 | 9.88 | 136.08K |
| Jun 10, 2026 | 9.96 | 10.67 | 9.91 | 10.33 | 97.03K |
| Jun 09, 2026 | 10.50 | 10.61 | 9.22 | 9.80 | 132.04K |
| Jun 08, 2026 | 10.23 | 10.82 | 8.75 | 10.31 | 304.42K |
| Jun 05, 2026 | 11.96 | 11.96 | 9.86 | 9.92 | 97.77K |
| Jun 04, 2026 | 12.00 | 12.55 | 11.28 | 11.89 | 125.43K |
| Jun 03, 2026 | 11.82 | 13.00 | 11.60 | 12.00 | 88.51K |
| Jun 01, 2026 | 11.35 | 11.71 | 11.17 | 11.44 | 31.53K |
| May 29, 2026 | 11.38 | 11.55 | 11.05 | 11.25 | 17.44K |
| May 28, 2026 | 11.70 | 12.32 | 11.17 | 11.54 | 37.05K |
| May 27, 2026 | 11.28 | 11.85 | 10.82 | 11.67 | 55.3K |
| May 26, 2026 | 11.77 | 11.77 | 11.00 | 11.05 | 87.43K |
| May 22, 2026 | 11.05 | 11.55 | 10.98 | 11.50 | 34.11K |
| May 21, 2026 | 10.55 | 11.03 | 10.55 | 10.94 | 27.86K |
| May 20, 2026 | 10.58 | 10.82 | 10.49 | 10.70 | 38.02K |
| May 19, 2026 | 10.42 | 10.70 | 10.23 | 10.51 | 29.56K |
| May 18, 2026 | 10.25 | 10.57 | 10.10 | 10.56 | 64.39K |
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGF�R1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGF�R1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
| Employees | 57 |
| Beta | 0 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |